Bendamustine Hydrochloride and Rituximab Compared With R-CVP or R-CHOP in Patients With Lymphoma
- Study Title
- Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study
- Teva Identifier
- C18083/3064/NL/MN
- ClinicalTrials.gov Identifier
- NCT00877006
- Study Status
- Completed
- Trial Condition(s)
- Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma
- Interventions
- Drug: bendamustine | Drug: rituximab | Drug: vincristine | Drug: prednisone | Drug: cyclophosphamide | Drug: doxorubicin
- Study Description
- Please refer to ClinicalTrials.gov for a description of the trial
Key Participation Requirements
- Gender
- Female, Male
- Age group
- Adult, Older Adult
- Age Range
- 18 Years and older
- Trial Duration
- April 30, 2009 - March 31, 2012
- Phase
- Phase 3
